Clinical Trials Logo
  1. Home
  2. ARDS, Human
  3. NCT05491681

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial — ACE_CARD  

ARDS, Human Clinical Trial

Official title:
Phase I/IIa Study to Assess AllogeneiC Expanded Human Mesenchymal Stem Cell Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE CARD TRIAL)

Clinical Trial Summary

Allogeneic culture-expanded bone marrow-derived human mesenchymal stem cells (MSC) are the subject of the current study as they are supported by preclinical and clinical data for potential to provide a safe and effective treatment for patients with acute respiratory distress.

Clinical Trial Description

The majority of Covid-19 cases either are asymptomatic or result in only mild disease. However, in a substantial percentage of patients, a respiratory illness requiring hospital care develops, and such infections can progress to critical illness with hypoxemic respiratory failure requiring prolonged ventilatory support (Zhou 2020) , (Chen 2020) , (Cao 2020) , (Ruan 2020) . Among patients with Covid-19 who have been admitted to hospitals in the United Kingdom, the case fatality rate has been approximately 26%, a percentage that has increased to more than 37% among patients who were undergoing invasive mechanical ventilation.(Docherty 2020) Although remdesivir has been shown to shorten the time until recovery in hospitalized patients, (Beigel 2020). Efforts to modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death have shown promising results. INVESTIGATIONAL PRODUCT The NK1R+ MSC cell therapy are allogeneic bone marrow-derived mesenchymal stem cells that will be delivered intravenously. Details on cell culture and expansion of the cells are provided in the Chemistry Manufacturing and Controls Section of the IND. Cells are provided cryopreserved and are thawed, washed, and prepared for IV delivery. STUDY OBJECTIVES The objective of this clinical trial is to determine the safety and the optimal cell dose of the NK1R+ hMSC in patients recovering from ARDS. . ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05491681
Study type Interventional
Source BioCardia, Inc.
Contact Patrick S Lee, MS
Phone 6505041915
Email plee@biocardia.com
Status Not yet recruiting
Phase Phase 1
Start date August 2024
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05306392 - Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation N/A
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT04274296 - Advisory Lead ARDS Respirator Management
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Recruiting NCT03215316 - Screening Expiratory Flow Limitation by Flow-time Curve N/A
Recruiting NCT04115514 - Treatment of ARDS With Instilled T3 Phase 2
Not yet recruiting NCT05061212 - The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
Completed NCT05693051 - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Not yet recruiting NCT04556864 - Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
Recruiting NCT04174014 - Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography N/A
Enrolling by invitation NCT06164639 - Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
Terminated NCT05384379 - Efficacy and Safety Evaluation of BZ371B in ARDS Patients Early Phase 1
Completed NCT04375735 - London's Exogenous Surfactant Study for COVID19 Phase 1/Phase 2
Completed NCT06224010 - Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
Not yet recruiting NCT04530188 - Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS Phase 3
Completed NCT03405038 - Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
Not yet recruiting NCT06119516 - Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. N/A
Recruiting NCT05148026 - Regional Citrate Anticoagulation for RRT During V-V ECMO N/A
Recruiting NCT04390360 - Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction N/A
Active, not recruiting NCT04382391 - Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms N/A